BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for North American Extreme

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $4354.20.64 only $1741.68

ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.89
-0.24%
US Tech 100
20,607.20
1.07%
S&P 500
6,047.15
0.81%
US Dollar vs CAD
1.40597
0.11%
Bitcoin
95,869.13
0.01%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Calithera Biosciences Inc (CALA) Share Price

Calithera Biosciences Inc

Calithera Biosciences Inc (CALA)

Calithera Biosciences Inc (CE)
0.20
0.00
(0.00%)
Closed December 02 3:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
0.20
Bid
0.16
Ask
0.35
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
974.499k
Previous Close
0.20
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
4,872,497
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-4.37
Revenue
-
Net Profit
-21.29M

About Calithera Biosciences Inc

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumo... Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.calithera.com
Headquarters
Wilmington, Delaware, USA
Founded
-

Ask ADVFN Intelligence (AI)

CALA Latest News

More News

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: “CALA”). Calithera Biosciences, Inc. (the “Company”) announced that it was unable to achieve a...

June 29 2023
GlobeNewswire Inc.

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: CALA) (the “Company”) announced that it intends to hold a special meeting of stockholders on or...

May 19 2023
GlobeNewswire Inc.

Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive...

January 09 2023
GlobeNewswire Inc.

Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its...

November 14 2022
GlobeNewswire Inc.

Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced...

November 08 2022
GlobeNewswire Inc.

Calithera Biosciences Gets FDA Fast Track For Lung Cancer Drug

By Will Feuer Calithera Biosciences Inc. said the U.S. Food and Drug Administration has granted fast-track designation for the company's investigational treatment for adults with unresectable...

October 03 2022
Dow Jones News

Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that...

October 03 2022
GlobeNewswire Inc.

Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that...

September 06 2022
GlobeNewswire Inc.

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its...

August 15 2022
GlobeNewswire Inc.

Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced...

August 08 2022
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SNTISenti Biosciences Inc
US$ 10.09
(367.13%)
129.8M
PPBTPurple Biotech Ltd
US$ 8.359
(149.15%)
48.02M
GELSGelteq Ltd
US$ 3.8205
(92.95%)
1.41M
FOSLFossil Group Inc
US$ 2.35
(60.96%)
29.6M
FGLFounder Group Limited
US$ 4.48
(60.00%)
473.99k
MONDMondee Holdings Inc
US$ 0.375
(-47.20%)
2.89M
JYDJayud Global Logistics Ltd
US$ 0.6701
(-39.63%)
1.81M
TOIIWOncology Institute Inc
US$ 0.0122
(-35.45%)
929
IDAIT Stamp Inc
US$ 0.4565
(-33.84%)
12.88M
FOXXFoxx Development Holdings Inc
US$ 3.32
(-29.96%)
43.6k
SMCISuper Micro Computer Inc
US$ 42.00
(28.68%)
263.23M
XTIAXTI Aerospace Inc
US$ 0.04745
(5.68%)
177.38M
NVDANVIDIA Corporation
US$ 138.63
(0.27%)
170.53M
INTCIntel Corporation
US$ 23.93
(-0.50%)
150.48M
RGTIRigetti Computing Inc
US$ 3.035
(-0.49%)
134.81M

CALA Discussion

View Posts
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 2 years ago
maybe soon will see something
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 2 years ago
maybe soon will see something
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 2 years ago
looking close
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 2 years ago
cala soon something
👍️0
Renee Renee 2 years ago
CALA delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions
👍️0
kzivann kzivann 2 years ago
CALA dissolving. https://quantisnow.com/insight/3950020
👍️0
Mr. Zen Mr. Zen 2 years ago
Calithera continued to advance multiple vacuolar protein sorting-associated protein 4A (VPS4A) and VPS4B inhibitors through lead optimization and plans to share updates on this program by the end of 2022.
👍️0
Nealio Nealio 2 years ago
CALA - continues upward. 100% gain in last month, very good swing play. Drug data was good...float is very low at 4.X M shares.
👍️0
Nealio Nealio 2 years ago
CALA in play! Drug data and earnings report. Should move even higher on this news.
👍️0
Nealio Nealio 2 years ago
Chart looks very good atm.
👍️0
Nealio Nealio 2 years ago
Could be the start of a big run; or not. We shall see; with recent good news, I like the chances. Good luck to all!
👍️0
ttottip ttottip 3 years ago
Yes.
👍️0
ttottip ttottip 3 years ago
Good morning all! Hoping for a reversal today.
👍️0
ttottip ttottip 3 years ago
I'm not hesitating to buy at these levels!
👍️0
bandit007 bandit007 3 years ago
Took a few here. $CALA
👍️0
kzivann kzivann 3 years ago
Moving after hours.

CALA
👍️0
crudeoil24 crudeoil24 3 years ago
Calithera Biosciences shares are trading higher after Ladenburg Thalmann initiated coverage on the stock with a Buy rating and a $4 price target.

CALA
👍️0
TheFinalCD TheFinalCD 3 years ago
big move 45-74


$CALA
👍️0
glens0 glens0 3 years ago
$CALA .58 w/ $3 price upgrade out by Leerink
👍️0
Eagle1 Eagle1 3 years ago
Thank you
👍️0
crudeoil24 crudeoil24 3 years ago
Company discontinued its KEAPSAKE clinical trial.
👍️0
Eagle1 Eagle1 3 years ago
Hi why the drop here?
👍️0
0210 0210 3 years ago
Calithera Biosciences CALA Q3 EPS $(0.15) Beats $(0.23) Estimate, Sales $6.75M, and a 53.13 percent increase over losses of $(0.32) per share from the same period last year.

4:42 pm ET November 9, 2021 (Benzinga)
Calithera Biosciences (NASDAQ:CALA) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 34.78 percent. This is a 53.13 percent increase over losses of $(0.32) per share from the same period last year. The company reported $6.75 million in sales this quarter.
👍️0
0210 0210 3 years ago
right-on-the-money...-54% to $0.86-0.87, from $1.90 on 21x dmav (of only 1,082,848 daily moving average volume).

SOURCE: https://ih.advfn.com/stock-market/NASDAQ/calithera-biosciences-CALA/historical

👍️0
willlbone willlbone 3 years ago
Bid at 60% drop.
👍️0
TheFinalCD TheFinalCD 3 years ago
$CALA -40%

Calithera Biosciences, Inc. | Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial

https://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-announces-decision-discontinue-keapsake
👍️0
Elgordo84 Elgordo84 4 years ago
I’m expecting earnings to be on the up tomorrow
Let’s go $CALA
👍️0
Elgordo84 Elgordo84 4 years ago
Looks like no one is paying attention
$CALA I guess is you and me!!!
Perfect for the run
While no one is watching.......
👍️0
Elgordo84 Elgordo84 4 years ago
Ok hello $CALA
I LIKE WHAT I SEE HERE!!!!
Let’s take this for a ride...
$CALA LETS GO —————>

👍️0
trade-stock000 trade-stock000 4 years ago
Cala when is the data due date? Thx
👍️0
oaps222 oaps222 4 years ago
Thanks for the info.
Geez~~, what a move. I wish I knew it last Thursday! LOL

In any event, congratulations, if you already got in ARTL!
👍️0
trade-stock000 trade-stock000 4 years ago
A-R-T-L is the one to watch (: PT $8-10
Add on correction price, read few post over there abt data and cocrystal CBD molecules. Apart from that it's focused on Lipid therapy the next frontier in Oncology.
👍️0
oaps222 oaps222 4 years ago
Very good point, but be careful. The market is crazy. I can see some (big?) corrections in the near future.
👍️0
oaps222 oaps222 4 years ago
From the recent 13G Filings, Adage Capital has reported its 4,000,000 shares of CALA (5.67% ownership) on Jan 13, 2021.
👍️0
trade-stock000 trade-stock000 4 years ago
Yeah but in Jan that was not much of an update, that´s why stock plummeted, company needs more time.

Jan option price rose becoz of that reason, now fade out. Will visit this ticker later, for now it´s waste of cash esp when whole market is running nut
👍️0
oaps222 oaps222 4 years ago
Was it on Jan 15-17, not Feb 15-17?
http://www.calithera.com/wp-content/uploads/2021/01/Arginase-1158-203-Poster.pdf
👍️0
trade-stock000 trade-stock000 4 years ago
IV surges in the event of future price move. $5 call for Feb 19 it seems someone very bullish abt this stock and bot calls. Article u cited it's from Jan-13th, today its 13th Feb (:, unless next week something comes out which is highly unlikely.
👍️0
oaps222 oaps222 4 years ago
I was doing a DD on CALA and found the following. I don't quite understand it. Can you share your thoughts on this?
"Implied Volatility Surging for Calithera Biosciences (CALA) Stock Options"

https://finance.yahoo.com/news/implied-volatility-surging-calithera-biosciences-134001483.html
👍️0
trade-stock000 trade-stock000 4 years ago
2.42 or lower test first before go up i hope
👍️0
trade-stock000 trade-stock000 4 years ago
CALA on Feb 15-17 presenting Biliary-Tract Cancer-Data-could do-vroomvroom
👍️0
jondoeuk jondoeuk 4 years ago
ASH abstract https://ash.confex.com/ash/2020/webprogram/Paper137266.html
👍️0
ClayTrader ClayTrader 5 years ago
* * $CALA Video Chart 12-23-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
cashbyers cashbyers 5 years ago
9.5M block trade today @ $4.45.. 17% stake or $42M investment...
👍️0
ClayTrader ClayTrader 5 years ago
* * $CALA Video Chart 11-19-19 * *

Link to Video - click here to watch the technical chart video

👍️0
jonny_red jonny_red 5 years ago
4 Penny Stocks To Watch In November After Latest Milestones

$GTBP $CALA $AVDL $BLCM

https://www.transparenttraders.me/2019/11/4-penny-stocks-to-watch-in-november.html
👍️0
cashbyers cashbyers 5 years ago
Long CALA @ $2.60
👍️0
buypumps buypumps 5 years ago
Conference call Monday also. Could push to 3.90 area.
👍️0
Zmill Zmill 5 years ago
TA of CALA https://msmoneymoves.com/2019/07/12/calithera-initiates-potential-buying-opportunity/
👍️0
CashBowski CashBowski 5 years ago
CALA going to close the gap today.
👍️0
Zmill Zmill 5 years ago
Research mentioning CALA https://wordpress.com/block-editor/post/msmoneymoves.com/11262
👍️0

Your Recent History

NASDAQ
CALA
Calithera Biosciences
USOTC
FUJHY
Subaru (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Canada: TSX and TSXV Level 1

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $1305.00 only $522.00